Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
2 hedge funds and large institutions have $4K invested in Northwest Biotherapeutics, Inc. Common stock in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
50% less funds holding
Funds holding: 4 → 2 (-2)
86% less capital invested
Capital invested by funds: $29K → $4K (-$25K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MBT
Montecito Bank & Trust
Santa Barbara,
California
|
-$19K |
| 2 |
WPP
Whalerock Point Partners
Providence,
Rhode Island
|
-$5K |
NWBO Hedge Fund Activity: Q2 2017 in Review
2 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2017, worth a combined $4K — down 86% from $29K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NWBO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Montecito Bank & Trust, exiting entirely with an estimated $19K sold.
- 2 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2017, down from 4 in Q1 2017.
- Funds reported $4K of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2017, down 86% quarter-over-quarter.
- 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2017 and 2 closed out, a net change of -2 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2017 was Montecito Bank & Trust, an estimated $19K sold.
Based on aggregated 13F filings for Q2 2017.